Inform Diagnostics, the largest U.S. independent anatomic pathology lab,
has expanded its
InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the
addition of Stelara (ustekinumab).
Inform Diagnostics continues to perform therapeutic drug monitoring (TDM)
for Remicade® (infliximab), Humira® (adalimumab), Cimzia®
(Certolizumab pegol) and Entyvio® (vedolizumab). Since launching in
June this year, the company’s InformTx TDM service is the first
time that TDM has been available in the United States for Cimzia and Entyvio.
Unique for TDM in the United States, the InformTx report provides clinicians
with quantitative test results, historical test result data, and guidance
from the most up-to-date peer-reviewed scientific literature. Inform Diagnostics Life
Sciences uses laboratory-validated ELISA technology for InformTx TDM,
and testing results are reported within five days.
“Increasing the number of drugs which we can test with our InformTx
therapeutic drug monitoring allows us to provide critical information
to help guide therapy for even more gastroenterologists and their patients,” said
Richard Lash, MD, Chief Medical Officer and Executive Vice President of Operations for
Inform Diagnostics. “We plan to add more biologics to our InformTx
testing service over time.”
Why Therapeutic Drug Monitoring?
Clinicians choose therapeutic drug monitoring for their patients because
individual response to biologic drugs varies greatly. Factors influencing
individual patient response to biologic therapy include systemic inflammation,
other drug therapies, pharmacogenetic factors, disease phenotype, body
mass, immunogenicity, immunomodulators, and the presence of anti-drug
antibodies. Variability by patients leads to four patient types: responders,
initial responders, partial responders, and non-responders. InformTx enables
clinicians to manage all patient types, across five different biologic
drugs used to treat IBD.
About Inform Diagnostics
Inform Diagnostics provides proven high-quality anatomic and clinical
pathology services, focusing on the fields of dermatology, hematology,
gastroenterology, urology, and breast health. The company’s team
of nearly 90 distinguished subspecialist pathologists utilizes state-of-the-art
laboratories to serve more than 5,500 patients every day. Inform Diagnostics Life
Sciences’ difference is based on consensus-based medicine (including
comprehensive sub-subspecialization, unified terminology and criteria,
daily consensus conferences, extensive educational activities), rigorous
quality assurance, active clinical research, innovation in testing, technological
advancements, and health IT consulting services for clinician clients.
Headquartered in Irving, Texas, Inform Diagnostics is a subsidiary of
Inform Diagnostics Holdings Inc., one of Japan’s largest clinical diagnostics
and laboratory testing service providers. For more information, visit
Stelara and Remicade are registered trademarks of Janssen Biotech, Inc.
Humira is a registered trademark of AbbVie Inc. Cimzia is a registered
trademark of UCB. Entyvio is a registered trademark of Millennium Pharmaceuticals Inc.